Acute phase reactant dynamics and incidence of microvascular dysfunctions in type 2 diabetes mellitus

Journal of Research in Medical Sciences

Volumn 16, Issue 10, 2011, Pages 1298-1305

  Azenabor, Alfred ^a   Ogbera, Anthonia O ^b   Adejumo, Ngozi E ^c   Adejare, Adejimi O ^d  

^a UNIVERSITY OF LAGOS   (Nigeria)

^b LAGOS STATE UNIVERSITY TEACHING HOSPITAL   (Nigeria)

^c BABCOCK UNIVERSITY   (Nigeria)

^d LAGOS UNIVERSITY TEACHING HOSPITAL   (Nigeria)

Author keywords

Acute Phase Reactants; Microvascular Complications; Type 2 Diabetes Mellitus

Indexed keywords

BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CREATININE; FIBRINOGEN; LIPOPROTEIN; UREA;

ACUTE PHASE RESPONSE; ADULT; ARTICLE; BLOOD ANALYSIS; CASE CONTROL STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; CREATININE BLOOD LEVEL; DIABETIC FOOT; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; FEMALE; GLYCEMIC CONTROL; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPHTHALMOSCOPY; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; PROTEINURIA; SCORING SYSTEM; UREA BLOOD LEVEL;

EID: 80955151105     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Crook MA, Tutt P, Simpson H, Pickup JC. Serum sialic acid and acute phase proteins in type 1 and type 2 diabetes mellitus. Clin Chim Acta 1993; 219(1-2): 131-8.
2. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40(11): 1286-92.
3. McMillan DE. Further observations on serum viscosity changes in diabetes mellitus. Metabolism 1982; 31(3): 274-8.
4. Bergsrand CG, Furst P, Larsson Y, Sterky G. Serum haptoglobin in juvenile diabetes. Scand J Clin Lab Invest 1962;14: 629-32.
5. Ganrot PO, Gydell K, Ekelund H. Serum concentration of alpha-2-macroglobulin, haptoglobin and alpha-1-antitrypsin in diabetes mellitus. Acta Endocrinol (Copenh) 1967; 55(3): 537-44.
6. Schalkwijk CG, Poland DC, van DW, Kok A, Emeis JJ, Drager AM, et al. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 1999; 42(3): 351-7.
7. Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol 1999; 19(12): 3071-8.
8. Okeoghene OA, Azenabor A. Glycaemic indices and non-traditional biochemical cardiovascular disease markers in a diabetic population in Nigeria. J Coll Physicians Surg Pak 2011; 21(8): 455-9.
9. Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Pagano G, et al. Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 2003; 26(7): 2150-5.
10. Klein RL, Hunter SJ, Jenkins AJ, Zheng D, Semler AJ, Clore J, et al. Fibrinogen is a marker for nephropathy and peripheral vascular disease in type 1 diabetes: studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort. Diabetes Care 2003; 26(5): 1439-48.
11. Haffner SM, Tuttle KR, Rainwater DL. Lack of change of lipoprotein (a) concentration with improved glycemic control in subjects with type II diabetes. Metabolism 1992; 41(2): 116-20.
12. Ramirez LC, Arauz-Pacheco C, Lackner C, Albright G, Adams BV, Raskin P. Lipoprotein (a) levels in diabetes mellitus: relationship to metabolic control. Ann Intern Med 1992; 117(1): 42-7.
13. Clodi M, Oberbauer R, Bodlaj G, Hofmann J, Maurer G, Kostner K. Urinary excretion of apolipoprotein(a) fragments in type 1 diabetes mellitus patients. Metabolism 1999; 48(3): 369-72.
14. Okuno S, Ishimura E, Kohno K, Fujino-Katoh Y, Maeno Y, Yamakawa T, et al. Serum beta2-microglobulin level is a significant predictor of mortality in maintenance haemodialysis patients. Nephrol Dial Transplant 2009; 24(2): 571-7.
15. Meijer JW, Smit AJ, Sonderen EV, Groothoff JW, Eisma WH, Links TP. Symptom scoring systems to diagnose distal polyneuropathy in diabetes: the Diabetic Neuropathy Symptom score. Diabet Med. 2002; 19(11): 962-5.
16. INGRAM GI. A suggested schedule for the rapid investigation of acute haemostatic failure. J Clin Pathol 1961; 14: 356-60.
17. Barham D, Trinder P. An improved colour reagent for the determination of blood glucose by the oxidase system. Analyst 1972; 97(151): 142-5.
18. Caplice NM, Panetta C, Peterson TE, Kleppe LS, Mueske CS, Kostner GM, et al. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood 2001; 98(10):2980-7.
19. Pu LJ, Lu L, Xu XW, Zhang RY, Zhang Q, Zhang JS, et al. Value of serum glycated albumin and high-sensitivity C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes.Cardiovasc Diabetol 2006; 5: 27.
20. Bruno G, Cavallo-Perin P, Bargero G, Borra M, D'Errico N, Pagano G. Association of fibrinogen with glycemic control and albumin excretion rate in patients with non-insulin-dependent diabetes mellitus. Ann Intern Med 1996; 125(8): 653-7.
21. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329(14): 977-86.
22. Ogbera AO, Azenabor AO. Lipoprotein (a), C-reactive protein and some metabolic cardiovascular risk factors in type 2 DM.Diabetol Metab Syndr 2010; 2: 51.
23. Famodu AA, Ojogwu LI, Jaiyesimi AEA, Okpere B, Laewor, M. Effect of insulin therapy of fibrinolytic activity in nigerians with insulin dependent diabetes. International Diabetes Digest 1999: 668-9.
24. Reid HL. Sex variation in plasma fibrinogen levels in Enugu, Nigeria. West Afr J Med 1984; 3: 195-9.
25. Utterman G. Lipoprotein (a): A genetic risk factor for premature coronary heart disease. Curr Opin Lipidol 1990: 1;404 -10.
26. Scanu AM, Fless GM. Lipoprotein (a). Heterogeneity and biological relevance. J Clin Invest 1990; 85(6): 1709-15.
27. Khare KC, Raman PG, Bhatnagar AD, Bhavsar R. Serum Lp(a) levels in patients of Diabetes Mellitus. Int J Diab Dev Countries 2000; 20: 79-83.
28. Guerci B, Meyer L, Sommer S, George JL, Ziegler O, Drouin P, et al. Severity of diabetic retinopathy is linked to lipoprotein (a) in type 1 diabetic patients. Diabetes Metab 1999; 25(5): 412-8.
29. Rema M, Mohan V, Snehalatha C. Acute phase serum proteins in diabetic retinopathy. Indian J Ophthalmol 1996; 44(2): 83-5.
30. Fujino A, Watanabe T, Kunii H, Yamaguchi N, Yoshinari K, Watanabe Y, et al. Lipoprotein(a) is a potential coronary risk factor. Jpn Circ J 2000; 64(1): 51-6.
31. Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 1989; 80(5): 1313-9.
32. Laycock JF, Lee J, Wise PH. Essential Endocrinology. 2nd ed. Oxford: Oxford University Press; 1983. p. 299-306.